AtriCure (NASDAQ:ATRC) Stock Rating Upgraded by Freedom Capital

2026-04-03 08:24:42 ET

AtriCure ( NASDAQ:ATRC – Get Free Report ) was upgraded by equities researchers at Freedom Capital to a “strong-buy” rating in a report released on Wednesday, Zacks.com reports.

A number of other research firms also recently commented on ATRC. Needham & Company LLC restated a “buy” rating and issued a $45.00 target price on shares of AtriCure in a research report on Thursday, February 12th. Canaccord Genuity Group lowered their price target on AtriCure from $64.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Citigroup reissued an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. UBS Group reduced their price objective on shares of AtriCure from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Finally, Zacks Research cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, AtriCure has a consensus rating of “Moderate Buy” and an average target price of $48.43.

View Our Latest Stock Analysis on AtriCure

AtriCure Stock Up 2.7%

Shares of NASDAQ ATRC opened at $29.07 on Wednesday. The company has a 50 day simple moving average of $32.30 and a 200-day simple moving average of $35.43. The company has a market capitalization of $1.45 billion, a P/E ratio of -121.13 and a beta of 1.43. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.96 and a quick ratio of 2.99. AtriCure has a 1 year low of $27.31 and a 1 year high of $43.18.

AtriCure ( NASDAQ:ATRC – Get Free Report ) last released its quarterly earnings data on Tuesday, February 17th. The medical device company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. The firm had revenue of $140.50 million for the quarter, compared to analysts’ expectations of $140.50 million. AtriCure had a negative return on equity of 1.15% and a negative net margin of 2.14%.The firm’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.33) earnings per share. On average, equities research analysts predict that AtriCure will post -0.6 earnings per share for the current year.

Insider Activity at AtriCure

In other news, insider Vinayak Doraiswamy sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $29.83, for a total transaction of $149,150.00. Following the completion of the transaction, the insider directly owned 96,875 shares of the company’s stock, valued at approximately $2,889,781.25. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website . Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC increased its position in shares of AtriCure by 13.3% in the 4th quarter. Hsbc Holdings PLC now owns 17,224 shares of the medical device company’s stock valued at $686,000 after purchasing an additional 2,028 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of AtriCure by 43.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,983 shares of the medical device company’s stock valued at $158,000 after purchasing an additional 1,205 shares in the last quarter. Invesco Ltd. lifted its position in shares of AtriCure by 7.9% during the 4th quarter. Invesco Ltd. now owns 74,435 shares of the medical device company’s stock worth $2,945,000 after purchasing an additional 5,462 shares during the last quarter. Mackenzie Financial Corp grew its stake in shares of AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after purchasing an additional 683 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of AtriCure by 88.0% during the fourth quarter. XTX Topco Ltd now owns 11,069 shares of the medical device company’s stock worth $438,000 after purchasing an additional 5,182 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

( Get Free Report )

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Featured Articles

• Five stocks we like better than AtriCure